Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.57 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | HPGD | P15428 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13980461 | 0.80 | NPC1 (0.55) | CSNK2A2CSNK2BCSNK2A1MAPTHPGD | |
| SCHEMBL3922827 | 0.80 | NPC1 (0.55) | CSNK2A2CSNK2BCSNK2A1MAPTHPGD | |
| SCHEMBL3925355 | 0.80 | NPC1 (0.55) | CSNK2A2CSNK2BCSNK2A1MAPTHPGD | |
| SCHEMBL3934054 | 0.80 | MAPT (0.57) | CSNK2A2CSNK2BCSNK2A1MAPTHPGD | |
| SCHEMBL13980459 | 0.76 | NPC1 (0.51) | CSNK2A2CSNK2BCSNK2A1MAPTHPGD | |
| SCHEMBL3932001 | 0.76 | ESR1 (0.56) | CSNK2A2CSNK2BCSNK2A1MAPTHPGD | |
| SCHEMBL1740975 | 0.74 | SIRT1 (0.69) | CSNK2A2CSNK2BCSNK2A1MAPTHPGD | |
| SCHEMBL5433487 | 0.73 | CSNK2A2 (1.00) | CSNK2A2CSNK2BCSNK2A1MAPTHPGD | |
| SCHEMBL13980467 | 0.73 | ESR1 (0.48) | CSNK2A2CSNK2BCSNK2A1ESR2ESR1 | |
| SCHEMBL9669237 | 0.72 | MEN1 (0.68) | CSNK2A2CSNK2BCSNK2A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2005-02-17 | — | — | US | claimed |
| EP-1458700-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-22 | — | — | EP | claimed |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2003-09-11 | — | — | US | claimed |
| WO-2003051860-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | claimed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1458700-B1 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH CORP (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1458700-B1 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH CORP (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20060074128-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH (US) | 2006-04-06 | — | — | US | disclosed |
| US-7022733-B2 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2005-02-17 | — | — | US | disclosed |
| EP-1458700-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6774248-B2 | ANTICANCER AGENTS; ANTICHOLESTEROL AGENTS; COGNITION ACTIVATORS; RHEUMATIC DISEASES | WYETH | 2004-08-10 | — | — | US | disclosed |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2003-09-11 | — | — | US | disclosed |
| WO-2003051860-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074128-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, GPER1 | CSNK2A2 546/4885CSNK2B 833/4885CSNK2A1 459/4885 |
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, ESRRA | CSNK2A2 524/4885CSNK2B 719/4885CSNK2A1 472/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | CSNK2A2 482/4885CSNK2B 699/4885CSNK2A1 478/4885 |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, GPER1 | CSNK2A2 651/4885CSNK2B 923/4885CSNK2A1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.